TY - JOUR
T1 - Antipsychotic-induced weight gain
T2 - A comprehensive research synthesis
AU - Allison, David B.
AU - Mentore, Janet L.
AU - Heo, Moonseong
AU - Chandler, Linda P.
AU - Cappelleri, Joseph C.
AU - Infante, Ming C.
AU - Weiden, Peter J.
PY - 1999/11
Y1 - 1999/11
N2 - Objective: The purpose of this study was to estimate and compare the effects of antipsychotics - both the newer ones and the conventional ones - on body weight. Method: A comprehensive literature search identified 81 English- and non-English-language articles that included data on weight change in antipsychotic-treated patients. For each agent, a meta-analysis and random effects meta-regression estimated the weight change after 10 weeks of treatment at a standard dose. A comprehensive narrative review was also conducted on all articles that did not yield quantitative information but did yield important qualitative information. Results: Placebo was associated with a mean weight reduction of 0.74 kg. Among conventional agents, mean weight change ranged from a reduction of 0.39 kg with molindone to an increase of 3.19 kg with thioridazine. Among newer antipsychotic agents, mean increases were as follows: clozapine, 4.45 kg; olanzapine, 4.15 kg; sertindole, 2.92 kg; risperidone, 2.10 kg; and ziprasidone, 0.04 kg. Insufficient data were available to evaluate quetiapine at 10 weeks. Conclusions: Both conventional and newer antipsychotics are associated with weight gain. Among the newer agents, clozapine appears to have the greatest potential to induce weight gain, and ziprasidone the least. The differences among newer agents may affect compliance with medication and health risk.
AB - Objective: The purpose of this study was to estimate and compare the effects of antipsychotics - both the newer ones and the conventional ones - on body weight. Method: A comprehensive literature search identified 81 English- and non-English-language articles that included data on weight change in antipsychotic-treated patients. For each agent, a meta-analysis and random effects meta-regression estimated the weight change after 10 weeks of treatment at a standard dose. A comprehensive narrative review was also conducted on all articles that did not yield quantitative information but did yield important qualitative information. Results: Placebo was associated with a mean weight reduction of 0.74 kg. Among conventional agents, mean weight change ranged from a reduction of 0.39 kg with molindone to an increase of 3.19 kg with thioridazine. Among newer antipsychotic agents, mean increases were as follows: clozapine, 4.45 kg; olanzapine, 4.15 kg; sertindole, 2.92 kg; risperidone, 2.10 kg; and ziprasidone, 0.04 kg. Insufficient data were available to evaluate quetiapine at 10 weeks. Conclusions: Both conventional and newer antipsychotics are associated with weight gain. Among the newer agents, clozapine appears to have the greatest potential to induce weight gain, and ziprasidone the least. The differences among newer agents may affect compliance with medication and health risk.
UR - http://www.scopus.com/inward/record.url?scp=0032751075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032751075&partnerID=8YFLogxK
M3 - Article
C2 - 10553730
AN - SCOPUS:0032751075
SN - 0002-953X
VL - 156
SP - 1686
EP - 1696
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 11
ER -
